451 related articles for article (PubMed ID: 21627399)
1. Oral supplementation of turmeric attenuates proteinuria, transforming growth factor-β and interleukin-8 levels in patients with overt type 2 diabetic nephropathy: a randomized, double-blind and placebo-controlled study.
Khajehdehi P; Pakfetrat M; Javidnia K; Azad F; Malekmakan L; Nasab MH; Dehghanzadeh G
Scand J Urol Nephrol; 2011 Nov; 45(5):365-70. PubMed ID: 21627399
[TBL] [Abstract][Full Text] [Related]
2. Oral supplementation of turmeric decreases proteinuria, hematuria, and systolic blood pressure in patients suffering from relapsing or refractory lupus nephritis: a randomized and placebo-controlled study.
Khajehdehi P; Zanjaninejad B; Aflaki E; Nazarinia M; Azad F; Malekmakan L; Dehghanzadeh GR
J Ren Nutr; 2012 Jan; 22(1):50-7. PubMed ID: 21742514
[TBL] [Abstract][Full Text] [Related]
3. Pioglitazone reduces urinary protein and urinary transforming growth factor-beta excretion in patients with type 2 diabetes and overt nephropathy.
Katavetin P; Eiam-Ong S; Suwanwalaikorn S
J Med Assoc Thai; 2006 Feb; 89(2):170-7. PubMed ID: 16579002
[TBL] [Abstract][Full Text] [Related]
4. Effect of addition of silymarin to renin-angiotensin system inhibitors on proteinuria in type 2 diabetic patients with overt nephropathy: a randomized, double-blind, placebo-controlled trial.
Fallahzadeh MK; Dormanesh B; Sagheb MM; Roozbeh J; Vessal G; Pakfetrat M; Daneshbod Y; Kamali-Sarvestani E; Lankarani KB
Am J Kidney Dis; 2012 Dec; 60(6):896-903. PubMed ID: 22770926
[TBL] [Abstract][Full Text] [Related]
5. A comparative randomized and placebo-controlled short-term trial of aspirin and dipyridamole for overt type-2 diabetic nephropathy.
Khajehdehi P; Roozbeh J; Mostafavi H
Scand J Urol Nephrol; 2002; 36(2):145-8. PubMed ID: 12028688
[TBL] [Abstract][Full Text] [Related]
6. Additive antiproteinuric effect of pentoxifylline in patients with type 2 diabetes under angiotensin II receptor blockade: a short-term, randomized, controlled trial.
Navarro JF; Mora C; Muros M; García J
J Am Soc Nephrol; 2005 Jul; 16(7):2119-26. PubMed ID: 15917336
[TBL] [Abstract][Full Text] [Related]
7. [Cytokines in noninvasive diagnostics of diabetic nephropathy progression].
Senatorski G; Paczek L; Kropiewnicka E; Bartłomiejczyk I
Pol Merkur Lekarski; 2002 Nov; 13 Suppl 1():28-32. PubMed ID: 12621778
[TBL] [Abstract][Full Text] [Related]
8. Relative incidence of ESRD versus cardiovascular mortality in proteinuric type 2 diabetes and nephropathy: results from the DIAMETRIC (Diabetes Mellitus Treatment for Renal Insufficiency Consortium) database.
Packham DK; Alves TP; Dwyer JP; Atkins R; de Zeeuw D; Cooper M; Shahinfar S; Lewis JB; Lambers Heerspink HJ
Am J Kidney Dis; 2012 Jan; 59(1):75-83. PubMed ID: 22051245
[TBL] [Abstract][Full Text] [Related]
9. Urinary concentration of transforming growth factor-beta-inducible gene-h3(beta ig-h3) in patients with Type 2 diabetes mellitus.
Cha DR; Kim IS; Kang YS; Han SY; Han KH; Shin C; Ji YH; Kim NH
Diabet Med; 2005 Jan; 22(1):14-20. PubMed ID: 15606685
[TBL] [Abstract][Full Text] [Related]
10. Effect of allopurinol in decreasing proteinuria in type 2 diabetic patients.
Momeni A; Shahidi S; Seirafian S; Taheri S; Kheiri S
Iran J Kidney Dis; 2010 Apr; 4(2):128-32. PubMed ID: 20404423
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of omega-3 fatty acid supplementation on serum levels of tumour necrosis factor-alpha, C-reactive protein and interleukin-2 in type 2 diabetes mellitus patients.
Malekshahi Moghadam A; Saedisomeolia A; Djalali M; Djazayery A; Pooya S; Sojoudi F
Singapore Med J; 2012 Sep; 53(9):615-9. PubMed ID: 23023905
[TBL] [Abstract][Full Text] [Related]
12. Elevation of urinary betaig-h3, transforming growth factor-beta-induced protein in patients with type 2 diabetes and nephropathy.
Ha SW; Kim HJ; Bae JS; Jeong GH; Chung SC; Kim JG; Park SH; Kim YL; Kam S; Kim IS; Kim BW
Diabetes Res Clin Pract; 2004 Aug; 65(2):167-73. PubMed ID: 15223229
[TBL] [Abstract][Full Text] [Related]
13. [Effect of losartan on renal and cardiovascular complications of patients with type 2 diabetes and nephropathy].
Parving HH; Brenner BM; Cooper ME; de Zeeuw D; Keane WF; Mitch WE; Remuzzi G; Snapinn SM; Zhang Z; Shahinfar S
Ugeskr Laeger; 2001 Oct; 163(40):5514-9. PubMed ID: 11601117
[TBL] [Abstract][Full Text] [Related]
14. Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function.
van den Meiracker AH; Baggen RG; Pauli S; Lindemans A; Vulto AG; Poldermans D; Boomsma F
J Hypertens; 2006 Nov; 24(11):2285-92. PubMed ID: 17053552
[TBL] [Abstract][Full Text] [Related]
15. Pentoxifylline reduces proteinuria in insulin-dependent and non insulin-dependent diabetic patients.
Guerrero-Romero F; Rodríguez-Morán M; Paniagua-Sierra JR; García-Bulnes G; Salas-Ramírez M; Amato D
Clin Nephrol; 1995 Feb; 43(2):116-21. PubMed ID: 7736673
[TBL] [Abstract][Full Text] [Related]
16. Effect of thiazolidinedione treatment on proteinuria and renal hemodynamic in type 2 diabetic patients with overt nephropathy.
Pistrosch F; Passauer J; Herbrig K; Schwanebeck U; Gross P; Bornstein SR
Horm Metab Res; 2012 Nov; 44(12):914-8. PubMed ID: 22723267
[TBL] [Abstract][Full Text] [Related]
17. [Risk and prevention of diabetic nephropathy].
Ravera M; Re M; Deferrari G
G Ital Nefrol; 2007; 24 Suppl 38():13-9. PubMed ID: 17922442
[TBL] [Abstract][Full Text] [Related]
18. Angiotensin receptor blocker and N-acetyl cysteine for reduction of proteinuria in patients with type 2 diabetes mellitus.
Rasi Hashemi S; Noshad H; Tabrizi A; Mobasseri M; Tayebi Khosroshahi H; Heydarnejad M; Khalaj MR; Aghamohammadzadeh N
Iran J Kidney Dis; 2012 Jan; 6(1):39-43. PubMed ID: 22218118
[TBL] [Abstract][Full Text] [Related]
19. Influence of renal involvement on peripheral blood mononuclear cell expression behaviour of tumour necrosis factor-alpha and interleukin-6 in type 2 diabetic patients.
Navarro JF; Mora C; Gómez M; Muros M; López-Aguilar C; García J
Nephrol Dial Transplant; 2008 Mar; 23(3):919-26. PubMed ID: 17911088
[TBL] [Abstract][Full Text] [Related]
20. Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy.
Bolton WK; Cattran DC; Williams ME; Adler SG; Appel GB; Cartwright K; Foiles PG; Freedman BI; Raskin P; Ratner RE; Spinowitz BS; Whittier FC; Wuerth JP;
Am J Nephrol; 2004; 24(1):32-40. PubMed ID: 14685005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
